Compare TISI & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TISI | IPSC |
|---|---|---|
| Founded | 1973 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.9M | 58.3M |
| IPO Year | N/A | 2021 |
| Metric | TISI | IPSC |
|---|---|---|
| Price | $14.00 | $0.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 38.7K | ★ 1.4M |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $884,953,000.00 | $113,337,000.00 |
| Revenue This Year | N/A | $1,590.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 3.73 | ★ 4122.69 |
| 52 Week Low | $11.12 | $0.34 |
| 52 Week High | $24.25 | $1.19 |
| Indicator | TISI | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 45.68 | 71.04 |
| Support Level | $13.19 | $0.93 |
| Resistance Level | $14.58 | $0.62 |
| Average True Range (ATR) | 0.87 | 0.12 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 32.93 | 80.91 |
Team Inc provides specialty industrial services, including inspection, engineering assessment, and mechanical repair and remediation required in maintaining high-temperature and high-pressure piping systems and vessels utilized in refining, petrochemicals, and others. The company operates in two segments, Inspection and Heat Treating and Mechanical Services. The Inspection and Heat Treating segment, which generates maximum revenue, provides conventional and non-destructive testing services for the process, pipeline, and power sectors, pipeline integrity management services, and field heat treating services, as well as associated engineering and condition assessment services. Geographically, the company derives its key revenue from the United States, followed by other countries, and Canada.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.